Stealth BioTherapeutics Receives Refusal To File Letter From The FDA Updates
BOSTON, Oct. 20, 2021 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding Stealth’s New Drug Application (NDA) …
Stealth BioTherapeutics Receives Refusal To File Letter From The FDA Updates Read More »